Surveyor Capital
VC Fund
Chicago, United States
Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.
- Total investments:
- 170
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Surveyor Capital invests in
Stages Surveyor Capital invests in
Countries Surveyor Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $60M–$170M
- Series C
- $60M–$226M
- Post-IPO Equity
- $41M–$280M
Investment Focus
Industry
- Biotechnology 125 (74%)
- Health Care 81 (48%)
- Therapeutics 51 (30%)
- Pharmaceutical 48 (28%)
- Medical 42 (25%)
Stage
- Series B 62 (36%)
- Post-IPO Equity 41 (24%)
- Series C 29 (17%)
- Series A 17 (10%)
- Series D 5 (3%)
Country
- United States 114 (67%)
- China 4 (2%)
- Canada 3 (2%)
- Switzerland 3 (2%)
- United Kingdom 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Isai Peimer
Senior Analyst
|
Senior Analyst | Total investments: 2 | Find email | |
Joshua A.W. Mosberg
Analyst
|
Analyst | Total investments: 0 | Find email | |
Brad Lau
Deputy Chief Operating Officer
|
Deputy Chief Operating Officer | Total investments: 0 | Find email | |
Daniel Krizek
Portfolio Manager
|
Portfolio Manager | Total investments: 1 | Find email | |
Gerald A. Beeson
Senior Managing Director, Chief Operating Officer
|
Senior Managing Director, Chief Operating Officer | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M / Series C / Apr 14, 2026 | |
Sol-Gel Technologies
|
Sol-Gel designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds. | $33.1M / Post-IPO Equity / Mar 23, 2026 | |
Perspective Therapeutics
|
Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them. | $175M / Post-IPO Equity / Feb 02, 2026 | |
Soley Therapeutics
|
Soley Therapeutics combines AI with molecular and cellular response detection for developing new efficacious drugs, using image acquisition-based approaches.Soley Therapeutics has taken an orthogonal approach to discover new drugs by developing a technology platform to measure how cells respond multi-dimensionally in response to drugs. We havedeveloped a novel platform for high-content phenotypic drug screening, where the drug effect on a cell can be visualized via molecular-microscopic images and analyzed by using sophisticated AI tools. | $200M / Series C / Jan 07, 2026 | |
Triana Biomedicines
|
Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M / Series B / Dec 03, 2025 | |
Solve Therapeutics
|
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics. The company was founded in 2021 and is headquartered in Belmont, California. | $120M / Series A / Nov 17, 2025 | |
VeraDermics
|
Veradermics is a dermatology-focused biopharmaceutical company that develops treatments for common skin and hair conditions. Its lead drug candidate, VDPHL01, is an extended-release oral minoxidil being tested in Phase 3 clinical trials for pattern hair loss in both women and men. The company also has pipeline programs targeting conditions such ascommon warts, molluscum contagiosum, and atopic dermatitis. | $150M / Series C / Oct 16, 2025 | |
Adcytherix
|
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M / Series A / Oct 16, 2025 | |
Kailera Therapeutics
|
Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases. | $600M / Series B / Oct 14, 2025 | |
Oruka Therapeutics
|
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases. | $180M / Post-IPO Equity / Sep 17, 2025 | |
| See all 170 investments → | |||
Co-Investors
Logos Capital
60 deals together
RA Capital Management
57 deals together
OrbiMed
42 deals together
Janus Henderson Investors
39 deals together
Cormorant Asset Management
37 deals together
Perceptive Advisors
34 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Surveyor Capital invest in?
Surveyor Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Post-IPO Equity stage. Most of the 170 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Surveyor Capital's check size?
Surveyor Capital typically joins rounds of $60M–$170M at Series B, $60M–$226M at Series C and $41M–$280M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Surveyor Capital participates in.
How do I contact Surveyor Capital?
Public channels for Surveyor Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Surveyor Capital?
The team at Surveyor Capital includes Isai Peimer (Senior Analyst), Joshua A.W. Mosberg (Analyst) and Brad Lau (Deputy Chief Operating Officer), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
